These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 18421052)

  • 1. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
    Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
    J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
    Takimoto CH
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of novel agents for the treatment of colorectal cancer: a critical review of current practice and some suggestions for the future.
    Marshall JL; Gehan EA
    Clin Adv Hematol Oncol; 2007 Mar; 5(3):167-72. PubMed ID: 17519876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing tumor-related signs and symptoms to support cancer drug approval.
    Williams G; Pazdur R; Temple R
    J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long overdue: phase II studies in older cancer patients: where does the FDA stand?
    Balducci L; Tam-McDevitt J; Hauser R; Simon J
    J Clin Oncol; 2008 Mar; 26(8):1387-88. PubMed ID: 18323564
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
    Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
    Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and benefits associated with novel phase 1 oncology trial designs.
    Koyfman SA; Agrawal M; Garrett-Mayer E; Krohmal B; Wolf E; Emanuel EJ; Gross CP
    Cancer; 2007 Sep; 110(5):1115-24. PubMed ID: 17628485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM; Braiteh F; Stewart DJ; Kurzrock R
    J Clin Oncol; 2009 Dec; 27(36):6243-50. PubMed ID: 19826112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the treatment of metastatic colorectal cancer.
    Leong S; Messersmith WA; Tan AC; Eckhardt SG
    Cancer J; 2010; 16(3):273-82. PubMed ID: 20526106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II.
    Giacoia GP; Mattison DR
    Clin Ther; 2006 Sep; 28(9):1337-41. PubMed ID: 17062307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
    LoRusso PM; Boerner SA; Seymour L
    Clin Cancer Res; 2010 Mar; 16(6):1710-8. PubMed ID: 20215546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel designs and end points for phase II clinical trials.
    Adjei AA; Christian M; Ivy P
    Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.